Precigen is a biopharmaceutical company developing precision medicines in immuno-oncology, autoimmune disorders, and infectious diseases using proprietary technology platforms including UltraCAR-T, AdenoVerse immunotherapy, and synthetic biology tools. The company commercializes both pharmaceutical products—primarily its FDA-approved gene therapy for recurrent respiratory papillomatosis—and generates ancillary revenues through research model services, partnerships, and technology licensing. Precigen targets patients with rare and orphan indications as well as cancers with unmet medical needs, operating clinical trials and manufacturing facilities while pursuing a diversified revenue model combining product sales, service revenues, collaboration agreements, and licensing arrangements.